Investors — GutRecover Therapeutics

Investor presentation · 2026

For investors

The GutRecover investor presentation

A concise overview of the platform, pipeline, market opportunity, and the team building defined microbiome medicine. Watch the walkthrough or download the deck.

Request the deck → View pipeline →

01 — Why invest

A defensible position at an inflection point

GutRecover combines a proprietary strain library, a multi-omics discovery platform, and pharmaceutical-grade manufacturing — the components required to build a durable microbiome therapeutics company.

Proprietary strain library150+ characterised strains accumulated through structured isolation campaigns, maintained under strict access controls.
Defined consortia — no donor materialEvery candidate is a precisely defined community of characterised strains, enabling pharmaceutical-grade reproducibility and regulatory clarity.
Multi-omics discovery engineMetagenomics, metatranscriptomics, and metabolomics turn ecosystem data into reproducible, biomarker-driven medicine.
Phase 1-ready lead programGR-101 is IND-enabling for recurrent C. difficile infection — the same modality and indication as the first FDA-approved defined consortia — with two further programs behind it.^1,2
Growing IP portfolioComposition-of-matter and platform-method filings across key jurisdictions, anchored in a defensible discovery engine.
Backed by QADR BiotechnologyGutRecover advances as the therapeutic arm of the QADR group, with R&D and early manufacturing infrastructure in place.

// Strain-library and program counts are internal company metrics; GR-101 is shown at its honest IND-enabling / Phase 1-ready stage.

02 — Platform

A discovery platform, not a single product

The same multi-omics engine that produced GR-101 generates the rest of the pipeline — de-risking each successive program and compounding the value of the strain library.

01 — Profile

Map the disrupted ecosystem

Multi-omics profiling identifies which ecological functions are absent in disease and which strains restore them.

02 — Design

Engineer the consortium

Candidate consortia are designed against biomarker targets whose normalisation correlates with clinical resolution.

03 — Validate

Earn each claim

Germ-free models and pre-specified endpoints precede human studies — evidence before advancement, every time.

Explore the interactive platform →

03 — Market opportunity

A large, underserved market

Microbiome-driven disease spans gastrointestinal infection, inflammatory disease, and immune dysregulation — indications where current therapies fall short and defined consortia offer a differentiated approach. The first defined and standardised microbiome therapies reached FDA approval in 2022–2023, validating both the modality and the commercial path.^1,8

C. difficile infections · US / yr

~500^K

Estimated annual C. difficile infections in the United States.^25,26

First recurrences · US / yr

~83^K

Patients with at least one recurrence — GR-101's target population.²⁵

US adults with ulcerative colitis

~1.25^M

Living with UC in the US — GR-201's target indication.²⁷

Sources: US C. difficile burden — CDC Emerging Infections Program / NEJM (Lessa 2015; Guh 2020); US ulcerative colitis prevalence — Lewis et al. 2023. Full citations in Publications.

04 — Pipeline

Three programs from one platform

A staged portfolio across distinct indications, anchored by a clinical-stage lead program.

GR-101 Recurrent C. difficile infection Phase 1-ready

GR-201 Ulcerative colitis Preclinical

GR-301 Gut–immune axis (undisclosed) Discovery

Full interactive pipeline & trial detail →

05 — At a glance

What makes GutRecover different

Approach

Defined-consortium platform

Reproducible, characterised communities of bacteria — not donor-derived preparations — built for regulatory and clinical credibility.

Engine

Multi-omics discovery

A repeatable pipeline from ecosystem data to candidate consortium, compounding the value of every program and every strain.

Team

Experienced operators

Microbiology, clinical development, manufacturing, and company-building experience across three operating locations.

Moat

IP & manufacturing

Composition and method filings plus controlled fermentation manufacturing — a defensible position that is difficult to replicate.

06 — Optimising the funnel

A discovery funnel built to de-risk

Each stage is designed to fail fast and cheaply — concentrating capital on the candidates most likely to succeed in the clinic.

01

Identify

Real-world, multi-omics data reveal the causes of dysbiosis-driven disease, narrowing the search before any animal work begins.

02

Develop

Characterised strains from the proprietary library are assembled into ecologically rational consortia and tested against biomarker targets.

03

Optimise

Pre-specified endpoints and controlled manufacturing carry only the highest-probability candidates into clinical development.

07 — Events & webcasts

Upcoming events

Where to meet the GutRecover team and hear program updates.

Q2 2026 Conference presentation — defined consortia as a new LBP classConference Details →

Q3 2026 Investor update call — GR-101 IND-enabling progressWebcast Register →

Q4 2026 Microbiome therapeutics summit — platform overviewConference Details →

// Placeholder events — replace with confirmed dates, venues, and registration links.

08 — Presentations & resources

Downloads

Corporate investor presentationPDF · 2026 · placeholder Download Company fact sheetPDF · one-page · placeholder Download Pipeline overviewWeb · interactive View

// Placeholder resources — wire each to the actual asset before publication.

09 — Corporate governance

Built on credible structure

GutRecover operates with the governance discipline expected of a clinical-stage therapeutics company, scaled appropriately to its development phase.

Board of Directors

Founder-led, advisor-supported

Chaired by the Founder & CEO, with independent scientific and commercial directors to be appointed as the company scales. Placeholder structure.

Scientific oversight

Scientific Advisory Board

External counsel in microbiome science, gastroenterology, and regulatory science guides program decisions. See the SAB →

Governance documents

Policies & charters

Board charter, code of conduct, and committee mandates available to qualified investors on request. Placeholder.

// Governance details are clearly-marked placeholders — replace with the actual board, committees, and documents.

10 — Investor relations

Let's talk.

For the investor presentation, partnership inquiries, or to be added to our investor update list, reach the team directly.

Placeholder form — connect to your CRM or mailing provider before publication.